Summary of IN8bio Conference Call - February 05, 2026 Company Overview - **Company**: IN8bio (NasdaqGM:INAB) - **Focus**: Development of cellular therapies using gamma delta T cells - **Key Personnel**: William Ho (CEO), Dr. Larry Lamb (Chief Scientific Officer) [1][2] Core Programs and Pipeline - **Ongoing Programs**: - **INB-100**: Allogeneic cell therapy for leukemia patients undergoing transplantation, currently enrolling an expansion cohort with updated phase one data expected by year-end [3] - **INB-619**: T cell engager platform targeting CD19 for both oncology and autoimmune diseases [3] - **INB-200 and INB-400**: Genetically modified gamma-delta T cell programs targeting solid tumors, particularly glioblastoma [3][4] Glioblastoma Treatment Insights - **Mechanism of Action**: Targets the DNA damage response (DDR) pathway, which is fundamental to all cells, making it potentially applicable to various solid tumors [33] - **Clinical Trial Results**: - Patients treated with INB-200 and INB-400 showed a median progression-free survival (PFS) of 13 months, compared to 6.6 months in the control group [14] - Overall survival (OS) for treated patients reached 17.2 months, with some patients remaining progression-free for over 4 years [15][47] - No major toxicity signals or adverse events reported [11] T Cell Engager Platform - **INB-619**: A unique CD19 targeting T cell engager designed to minimize cytokine release syndrome (CRS) while effectively depleting B cells [22][27] - **Comparative Efficacy**: INB-619 demonstrated comparable or superior potency to existing B-cell depleters like Amgen's blinatumomab and Roche's mosunitumab, with a significantly wider therapeutic window [26][27] Financial and Operational Updates - **Recent Financing**: Raised $20.1 million led by Coastlands Capital, with participation from Franklin Templeton and other investors, providing runway through 2027 [28][50] - **Upcoming Milestones**: - Public peer-reviewed publication of glioblastoma data - FDA guidance on regulatory path for glioblastoma program - Mouse data for INB-619 expected by late summer [53] Additional Insights - **Market Positioning**: IN8bio has chosen not to pursue autoimmune diseases with cell therapies, focusing instead on oncology due to concerns about the safety and efficacy of existing treatments in that area [20] - **Histopathology Findings**: Analysis of treated patients showed significant infiltration of gamma-delta T cells, indicating effective targeting of tumors [19] Conclusion - IN8bio is making significant strides in the development of innovative therapies for glioblastoma and leukemia, with promising clinical results and a solid financial foundation to support ongoing research and development efforts [29]